Drugs’ Path to China Slows as Regulatory Delays Add Up, J&J Says
This article is for subscribers only.
The Chinese pharmaceutical market is becoming increasingly challenging for drug companies because of how long regulators there take to approve new medicines, Johnson & Johnson’s Chief Scientific Officer Paul Stoffels said.
“It takes much longer now to get products approved,” Stoffels said in an interview Wednesday at the World Economic Forum in Davos, Switzerland. “If there’s anything slowing us down in China it’s much more that than the economic situation.”